JAMA Neurol
Novel orexin agonist improves cognition in narcolepsy type 1
In a secondary analysis of the 8-week, phase 2 TAK-861-2001 randomized trial (NCT05687903), the oral orexin receptor 2–selective agonist oveporexton improved cognitive symptoms in adults with narcolepsy type 1. Among 112 participants (mean age, 34 years; 52% female), oveporexton led to placebo-adjusted gains across attention (Psychomotor Vigilance Task), memory (Continuous Paired Associate Learning), and executive function (One Back and Digit Symbol tests). Improvements relative to placebo were observed across all dose groups.
Clinical takeaway: Oveporexton may offer a targeted approach to address cognitive deficits in narcolepsy type 1 alongside core symptom management.
Source:
Lammers GJ, et al. (2025, December 8). JAMA Neurol. Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41359331/